The risk of developing irritable bowel syndrome (IBS) is greater among people who weighed less than 1,500 g at birth compared to those who weighed more than 1,500 g, and patients with a lower birthweight tend to develop the condition earlier than their heavier counterparts, according to study findings published online Sept. 28 in Gut.
The risk of developing irritable bowel syndrome (IBS) is greater among people who weighed less than 1,500 g at birth compared to those who weighed more than 1,500 g, and patients with a lower birthweight tend to develop the condition earlier than their heavier counterparts, according to study findings published online Sept. 28 in Gut.
Jennifer R. Harris, PhD, of the Norwegian Institute of Public Health in Oslo, Norway, and colleagues conducted a postal questionnaire of 12,700 Norwegian twins born in the 1960s and 1970s, with a 31-item checklist of illnesses and symptoms including IBS. In order to test the association between intrauterine growth and IBS, the investigators analyzed data from discordant monozygotic pairs.
Among the monozygotic pairs, there was 22.4% concordance with IBS, versus only 9.1% among dizygotic twins. After adjustment, subjects with low birthweight (below 1,500 g) were 2.4 times more likely to have IBS than those with a heavier birthweight. The symptoms developed 7.7 years earlier in subjects with low birthweight compared to those patients with higher birthweight.
Bengtson M-B, Ronning T, Vatn M, et al. IBS in twins: genes and environment. Gut. Published Online First: 28 September 2006. doi:10.1136/gut.2006.097287.
The benefits of concurrent fetal and maternal heart rate monitoring
April 15th 2024A recent study revealed that employing maternal heart rate monitoring alongside fetal heart rate monitoring during labor significantly decreases the incidence of neonatal encephalopathy and severe neonatal acidemia.
Read More
How vitamin C intake in pregnant smokers impacts offspring airway function trajectory
April 12th 2024Investigating the impact of prenatal vitamin C supplementation on lung function and wheeze occurrence in offspring of pregnant smokers, revealing insights into mitigating respiratory risks.
Read More
NAID report shows maternal COVID-19 vaccination protects newborns
April 4th 2024New research led by the National Institute of Allergy and Infectious Diseases reveals sustained antibody levels in infants born to vaccinated mothers, underscoring the importance of maternal vaccination in safeguarding newborns against COVID-19.
Read More
FDA grants FTD to nipocalimab for treating FNAIT
March 26th 2024The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.
Read More